163 related articles for article (PubMed ID: 37291330)
1. Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer.
Zhang Y; Fan S; Shan M; Zou W; Feng Y; Hou T; Liu X; Wang J
Sci Rep; 2023 Jun; 13(1):9352. PubMed ID: 37291330
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis.
Li P; Zhang R; Nie Z; Long M; Zhang G; Fu Z
Int J Gynecol Cancer; 2018 Jun; 28(5):1029-1037. PubMed ID: 29664843
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Wu Y; Jiang P; Chen Z; Li W; Dong B; Zhang Y
BMC Cancer; 2024 May; 24(1):589. PubMed ID: 38745137
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
5. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer.
Li J; Li Y; Wang H; Shen L; Wang Q; Shao S; Shen Y; Xu H; Liu H; Cai R; Feng W
BMC Cancer; 2023 Jan; 23(1):51. PubMed ID: 36641433
[TBL] [Abstract][Full Text] [Related]
7. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ
JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
[TBL] [Abstract][Full Text] [Related]
11. Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Kou L; Zhang T; Yang X; Peng S; Wang Y; Yuan M; Li M
Future Oncol; 2022 May; 18(16):1917-1915. PubMed ID: 35193379
[No Abstract] [Full Text] [Related]
12. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.
Deng C; Zhang N; Jiang S; Zhang H; Ma J; Zou W; Liu X; Hu C; Hou T
Sci Rep; 2022 Jul; 12(1):11978. PubMed ID: 35831424
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
Tian T; Gao X; Ju Y; Ding X; Ai Y
Arch Gynecol Obstet; 2021 Mar; 303(3):793-801. PubMed ID: 33009996
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of nedaplatin-based chemotherapy combined with radiotherapy for locoregional advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Zhan ZJ; Tao HY; Qiu WZ; Liu ZY; Zhang RX; Liao K; Li G; Yuan YW; Yuan TZ; Zheng RH
J Cancer; 2020; 11(23):6782-6789. PubMed ID: 33123269
[No Abstract] [Full Text] [Related]
15. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Zhang P; Xi M; Li QQ; Hu YH; Guo X; Zhao L; Liu H; Liu SL; Luo LL; Liu Q; Liu MZ
Oncotarget; 2016 Jul; 7(28):44686-44694. PubMed ID: 27183916
[TBL] [Abstract][Full Text] [Related]
16. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin.
Liang X; Liu Q; Yao W; Yang S
Medicine (Baltimore); 2022 Dec; 101(49):e31187. PubMed ID: 36626436
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
